Intended for healthcare professionals

Rapid response to:

Head To Head

Should we rename low risk cancers?

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.k4699 (Published 23 January 2019) Cite this as: BMJ 2019;364:k4699

Rapid Response:

Re: Should we rename low risk cancers?

I congratulate the Authors and Editors for having attracted the attention of the physicians on a really important and interesting topic of Oncology. However, in my opinion, the medical class around the world is not yet adequately prepared to address and resolve such a outstanding problem. Evaluating a malignancy as a low risk cancer, inevitably requires the knowledge of Oncological Terrain-Dependent, Inherited Reak Risk of cancer (1), divided into two subtypes, deactivated, in which oncogenesis has not yet begun, and activated, primum movens of the slow evolution towards the cancer (2).
In short, in the presence of an Inherited Real Risk of Cancer, its gravity parallels the local micro-angiological and microcirculatory situation (3). The severity of cancer in fact depends on the severity of the association existing between vasomotility (peripheral heart, according to Claudio Allegra) and vasomotion (dynamics of the relative nutritional capillary). Initially, the greater activity of vasomotility is able to ensure a sufficient peripheral flow-motion, resulting in a low level of the local Low Grade Chronic Inflammation, always present in all stages of cancer.
In malignancy, starting from birth, ie in the Oncological Terrain -Dependent, Inherited Real Risk, the physician inevitably observes bedside using a common phonendoscope tissue acidosis (4), which parallels the severity of the underlying disorder.
Only if the doctor is able to bedside assess the seriousness of the local inflammation can talk about low risk cancer, to be always eliminated with inexpensive Reconstructing Mitocondrial Quantum Therapy (5).
References.
1)Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm
2) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, www.travelfactory.it, Roma, 2009.
3) Sergio Stagnaro - Marina Neri Stagnaro. Microangiologia Clinica. A cura di Simone Caramel. e-book, www.sisbq.org, http://www.sisbq.org/uploads/5/6/8/7/5687930/microangiologiaclinicasbq20...
4) Sergio Stagnaro, Marchionni Marco, Caramel Simone. Inherited Real Risk of Glioblastoma: pre-clinical diagnosis and primary prevention with Quantum Biophysical Semeiotics. 2017. http://www.sisbq.org/uploads/5/6/8/7/5687930/irrglioblastoma.pdf
5) Caramel S., Marchionni M., Stagnaro S. Morinda citrifolia Plays a Central Role in the Primary Prevention of Mitochondrial-dependent Degenerative Disorders. Asian Pac J Cancer Prev. 2015;16(4):1675. http://www.ncbi.nlm.nih.gov/pubmed/25743850 [MEDLINE]

Competing interests: No competing interests

28 February 2019
Sergio Stagnaro
Director
Quantum Biophysical Semeiotic Research Laboratory
Via Erasmo Piaggio 23/8, 16039 Riva Trigoso, Genoa, Italy